Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1982 Mar;13(3):441-4.
doi: 10.1111/j.1365-2125.1982.tb01399.x.

A comparison of triprolidine and cyclizine on histamine (H1) antagonism, subjective effects and performance tests in man

Clinical Trial

A comparison of triprolidine and cyclizine on histamine (H1) antagonism, subjective effects and performance tests in man

M Hamilton et al. Br J Clin Pharmacol. 1982 Mar.

Abstract

1 The effects of triprolidine and cyclizine on the histamine skin response, performance tests and subjective effects were examined in a controlled, double-blind study in eight healthy volunteers. 2 Triprolidine was considerably more potent that cyclizine in inhibiting the skin response to histamine. Significant inhibition of flare size occurred at 1, 2 an 4 h after triprolidine 2.5 mg. A smaller but significant reduction occurred at 2 and 4 h after cyclizine 100 mg but not after the 50 mg dose. 3 Cyclizine 100 mg produced a significant increase in reaction time at 4.5 h compared with lactose. Smaller though non significant increases followed triprolidine and cyclizine 50 mg. 4 Subjective effects were seen only after cyclizine 100 mg when subjects were significantly more drowsy, feeble, muzzy, lethargic and dreamy than after lactose dummy. No significant changes followed triprolidine 2.5 mg or cyclizine 50 mg. 5 It was concluded that while cyclizine has antihistamine properties, these are weak compared with triprolidine, and are not seen with doses sufficiently low to avoid central nervous system impairment.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Br J Pharmacol Chemother. 1967 Aug;30(3):463-9 - PubMed
    1. Psychopharmacologia. 1969;16(2):115-27 - PubMed
    1. Neuropharmacology. 1971 Mar;10(21):181-91 - PubMed
    1. Eur J Clin Pharmacol. 1971 Sep;3(4):215-20 - PubMed
    1. Eur J Clin Pharmacol. 1975 Aug 14;8(6):455-63 - PubMed

LinkOut - more resources